1. Effect of oral linezolid on the pressor response to intravenous tyramine
- Author
-
Catherine Bolger, Claire Watkins, Catherine J. Painter, Mireille Cantarini, Elaine M. Gilmore, and Andrew Hughes
- Subjects
Adult ,Male ,Monoamine Oxidase Inhibitors ,medicine.drug_class ,Moclobemide ,Administration, Oral ,Tyramine ,Blood Pressure ,Placebo ,Body Mass Index ,chemistry.chemical_compound ,Oral administration ,Acetamides ,medicine ,Humans ,Pharmacology (medical) ,Infusions, Intravenous ,Volunteer ,Oxazolidinones ,Antibacterial agent ,Pharmacology ,Monoamine oxidase inhibitor ,Cross-Over Studies ,Linezolid ,Middle Aged ,Crossover study ,Pharmacodynamics ,chemistry ,Anesthesia ,medicine.drug - Abstract
Aims To investigate the effect of monoamine oxidase A inhibition from a single oral dose of linezolid on the pressor response to intravenous (i.v.) tyramine, using positive and negative controls to validate the methodology. Methods This placebo-controlled, three-period crossover study was conducted in 12 healthy male volunteers. Each volunteer received either one oral dose of moclobemide (300 mg), linezolid (600 mg), or placebo tablet followed by an i.v. tyramine pressor test until an increase in systolic blood pressure of at least 30 mmHg above baseline occurred. Each study day was separated by a 7-day washout period. The dose of tyramine required to raise the blood pressure by 30 mmHg (TYR30) was calculated for each oral treatment by linear interpolation between log-transformed doses of i.v. tyramine. The influence of body mass index (BMI) on TYR30 was also investigated. Results The tyramine sensitivity factor (ratio of the geometric least square mean TYR30 for placebo and active oral treatment) was 1.8 [90% confidence interval (CI) 1.6, 2.0, P
- Published
- 2004
- Full Text
- View/download PDF